AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 201 min read$RVTY

Senior Vice President of Global Operations Tajinder Vohra Sold A Bunch Of Shares In Revvity

Revvity, Inc. (NYSE:RVTY) SVP Tajinder Vohra sold shares worth $1.0M at $141, reducing his holding by 38%. No insider buying occurred in the past year. Insiders own 0.4% of shares, valued at $67M. The company has 2 identified warning signs.

Original reporting
simplywall.st
Published Sep 20, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 20, 2026, 2:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RVTY
Bearish
medium confidence
Mentioned
$RVTY
Relevance
4/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$RVTYBearishLow
01

Why it matters

The disclosed sale may prompt short‑term traders to watch Revvity for price weakness, though the overall impact is expected to be modest.

02

Market read

A single insider sale of modest size; limited trading relevance.

03

What to watch

Potential tax planning or personal liquidity needs may have driven the transaction.

Relevance 4/10Novelty 4/10Timing: reported Sep 20 2026

Background

The article summarizes a Form 4 filing showing an insider's recent share sale.

Company-level read

Ticker impact

$RVTYBearishMedium confidence
Context

Senior Vice President Tajinder Vohra sold ~US$1.0 M of Revvity shares at $141, cutting his holding by 38%.

Expected impact

Modest short‑term price dip as market digests the large insider sell.

Evidence & confidence

A senior exec off‑loading a sizable stake at a price below current market indicates possible concerns about valuation.

Market effects

Sector

Minimal impact on the broader life‑sciences equipment sector.

Regional

Limited to US investors tracking Revvity.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a signal of trouble.

Key entities

  • person
    Tajinder Vohra

    Senior Vice President of Global Operations at Revvity.

  • company
    Revvity, Inc.

    Life‑sciences instrumentation and solutions provider (NYSE:RVTY).

Read at source← All news

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min